|Flatiron Health co-founder Zach Weinberg|
Flatiron Health has revealed part of how it plans to develop into the disruptive force in cancer drug R&D that investors envisaged when they gave it $130 million in May. The latest piece of the plan is a deal with testing firm Foundation Medicine ($FMI), which will contribute genomic profiling data to a cancer analytics platform.
New York, NY-based Flatiron Health is bringing its OncologyCloud platform to the collaboration. The partners--both of which have received investment from Google ($GOOG) Ventures--plan to populate the platform with genomic profiling data from people who have used Foundation Medicine's tests. By matching the genomic testing results with clinical treatment and outcomes data, the partners hope to create a resource that can speed development of targeted cancer therapies.
"The marriage of information analytics and cancer genomics represents one of the most powerful opportunities to redefine and reshape the way cancer drugs are developed and delivered to patients in need," Foundation Medicine CEO Dr. Michael Pellini said in a statement. Possible uses for the cloud-based platform include drug candidate selection, clinical study design and patient recruitment into trials.
Exactly how the partners plan to turn their undoubted analytics chops and data resources into a tool that can help drug developers with these tricky tasks will become clear in 2015. The partners plan to make products available for licensing by life science companies by the middle of next year.
- read the release